NCT05032053 Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds
| NCT ID | NCT05032053 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2022-03-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2022-03-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To observe the effect of different antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds. And further combined with proteomic methods to explore serological markers that can be used to accurately predict the prognosis of such patients.
Eligibility Criteria
Inclusion Criteria: 1. Patients diagnosed clinically as ischemic stroke; 2. Age ≥ 40 years; 3. Onset time ≤ 3 months; 4. Informed consent was signed. Exclusion Criteria: 1. Patients with symptomatic intracranial hemorrhage; 2. bleeding lesion \> 10 mm was found on SWI; 3. Vascular malformations, tumors, abscesses or other major non ischemic brain diseases were present; 4. There are contraindications for antithrombotic drugs use; 5. Serious systemic diseases; 6. Refusal to sign informed consent or poor compliance.
Contact & Investigator
Wen Jiang, Ph.D
STUDY DIRECTOR
Department of Neurology, Xijing Hospital, Fourth Military Medical University
Frequently Asked Questions
Who can join the NCT05032053 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05032053 currently recruiting?
Yes, NCT05032053 is actively recruiting participants. Contact the research team at jiangwen@fmmu.edu.cn for enrollment information.
Where is the NCT05032053 trial being conducted?
This trial is being conducted at Ankang, China, Hanzhong, China, Xi'an, China, Ya'an, China and 11 additional locations.
Who is sponsoring the NCT05032053 clinical trial?
NCT05032053 is sponsored by Xijing Hospital. The principal investigator is Wen Jiang, Ph.D at Department of Neurology, Xijing Hospital, Fourth Military Medical University. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.